Mirati Therapeutics
Mirati Therapeutics, Inc. is an American targeted oncology company that focuses on the development of cancer therapeutics. Bristol Myers Squibb agreed to acquire the company in October 2023. History
Mirati Therapeutics works largely in KRAS-mutation inhibition, and developing treatments for tumors that contain it. The inhibition to the mutation has shown to shrink the size of its tumors. The company is based in San Diego, California. The company’s name comes from the Italian word for “targeted” (Mirati). Mirati Therapeutics is traded on the NASDAQ under the ticker symbol MRTX. It joined the exchange in 2013. In October 2023, Bristol Myers Squibb agreed to acquire the company in an all-cash deal worth $4.8 billion, and an additional $1 billion in milestone payment. Drug candidates
The company’s leading drug candidates are sitravatinib and adagrasib. Mirati also has a preclinical candidate against the G12D mutation. Management
The company’s CEO and President is David Meek. References

External links
 

2013 initial public offerings
Announced mergers and acquisitions
Companies listed on the Nasdaq
Biotechnology companies of the United States
Cancer organizations based in the United States
Companies based in San Diego